↑ 疾患リストへ ← 戻る

 202. スミス・マギニス症候群 [臨床試験数:6,薬物数:6(DrugBank:3),標的遺伝子数:2,標的パスウェイ数:2] 

Searched query = "Smith-Magenis syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03492970March 7, 20186 May 2019Melatonin in Adults With SMSCharacterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis SyndromeSmith Magenis SyndromeBiological: Hourly dosing of the nychtemeral secretion of melatoninHôpital le VinatierHospices Civils de LyonNot recruiting18 Years65 YearsAll10N/AFrance
2NCT03013543January 201730 September 2019Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of ObesitySetmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of ObesityPro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic);Leptin Receptor Deficiency Obesity;Bardet-Biedl Syndrome;Alstrom Syndrome;Smith-Magenis SyndromeDrug: SetmelanotideRhythm Pharmaceuticals, Inc.Recruiting12 YearsN/AAll80Phase 2/Phase 3United States;Spain;United Kingdom
3NCT02776215September 201616 December 2017Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsOpen-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsCircadian Rhythm Sleep Disorders;Non-24 Hour Sleep-Wake Disorder;Autism Spectrum Disorder;Smith-Magenis SyndromeDrug: tasimelteonVanda PharmaceuticalsRecruiting3 Years17 YearsAll24Phase 1United States
4NCT02231008September 201523 May 2016Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMSSmith-Magenis Syndrome;CircadianDrug: tasimelteonVanda PharmaceuticalsRecruiting16 Years65 YearsBoth48Phase 2/Phase 3United States
5NCT00506259July 17, 200711 November 2019Treatment Strategies for Children With Smith-Magenis SyndromeA Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)Developmental Delay Disorders;Chromosome Deletion;Mental Retardation;Sleep Disorders, Circadian Rhythm;Self Injurious BehaviorDrug: dTR Melatonin (NIH CC PDS);Device: Phototherapy (Bright Light);Drug: Melatonin CRNational Human Genome Research Institute (NHGRI)Not recruiting3 Years45 YearsAll23Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00691574September 199819 February 2015Melatonin Levels in Smith Magenis Syndrome (SMS)Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot StudyChromosome DisordersDietary Supplement: Melatonin;Device: Enviro-light artificial light boxOregon Health and Science UniversityNot recruiting3 Years85 YearsBoth5N/AUnited States

先頭へ